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Abstract
Background: In the UK, urinary tract infections (UTIs) are the most common bacterial infection presented by women in
primary care. Recurrent urinary tract infections (RUTIs) are defined as three episodes of UTI in the last 12 months, or two
episodes in the last 6 months. Between 20 and 30 % of women who have had one episode of UTI will have an RUTI, and
approximately 25 % of these will develop subsequent recurrent episodes. RUTIs can have a significant negative effect on
the quality of life, and have a high impact on health care costs as a result of outpatient visits, diagnostic tests and
prescriptions. Chinese herbal medicine (CHM) has a recorded history of treatments for the symptoms of UTIs for
more than 2000 years. More recent clinical research in China has provided some preliminary evidence that CHM
can alleviate the symptoms of UTIs and reduce the rate of recurrence, but more rigorous investigation is required.
Methods/design: The RUTI trial is a double-blind, randomised, placebo-controlled, feasibility trial. A total of 80
women will be randomised to ‘individualised’ herbs prescribed by a Chinese herbal practitioner or to ‘standardised’
herbs provided by primary care clinicians. Both arms will have herbs for prevention of UTIs and treatment of acute
episodes. Treatment duration is for 16 weeks.
The primary outcomes are the number of episodes of recurrent UTIs during the trial period and in the 6 months
of follow-up, and the number of days of symptoms rated moderately bad or worse based on patient diaries.
Secondary outcomes will assess participant expectations and beliefs, adherence to the treatment, adverse events
and health economics and provide quantitative and qualitative assessments of the impact of recurrent infections
on the lives of women.
(Continued on next page)
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Discussion: The RUTI trial is the first instance of CHM delivered as a clinical trial of an investigatory medicinal
product in the UK. This study provides important information regarding the feasibility and acceptability of
researching and using CHM in Primary care. Once completed, it will provide provisional estimates of the variance
of change in continuous outcomes to inform a power calculation for a larger, more definitive trial.
Trial registration: EudraCT, 2013-004657-24. Registered on 5 September 2014.
Keywords: Urinary tract infection, Chinese herbal medicine, Primary care, feasibility
Background
Epidemiology and current management
In the UK, urinary tract infections (UTIs) are the most
common bacterial infection presented by women in the
primary care setting [1, 2], with approximately 40–50 %
of women experiencing one episode during their lives
[3]. This accounts for between 1–3 % of all consultations
in general practice [4].
Recurrent urinary tract infections (RUTIs) are com-
monly defined in the literature as three episodes of UTI
in the last 12 months or two episodes in the last
6 months [5]. Between 20 and 30 % of women who have
had one episode of UTI will have a recurrent UTI and
approximately 25 % of these will develop subsequent re-
current episodes [6, 7]. RUTIs can have a significant
negative effect on the quality of life [8] and have a high
impact on healthcare costs as a result of outpatient
visits, diagnostic tests and prescriptions.
Antibiotics are currently the mainstay treatment for
both acute and recurrent UTIs. Whilst antibiotics may
be effective in reducing the duration of severe symptoms
in acute episodes [9, 10], antibiotic resistance is currently
estimated at 20 % for trimethoprim and cephalosporins
and 50 % for amoxicillin [11]. Antibiotic resistance and
previous episodes of cystitis have been positively associ-
ated with an increased duration of severe symptoms of
UTIs [2]. It is predicted that antibiotic resistance will con-
tinue to increase [12]. The UK government and Chief
Medical Officer for England have indicated the need to
consider alternatives to antibiotics [13].
Antibiotic prophylaxis is, however, used to prevent
RUTIs. Treatment usually lasts for between 6 and
12 months but can be extended for up to 5 years [14].
A Cochrane systematic review of antibiotics used to
prevent RUTIs in non-pregnant women found that
antibiotics given continuously for 6–12 months were
significantly more able than placebo to prevent recur-
rent infection (RR 0.15 (95 % CI 0.08 to 0.28 and NNT
1.85 (CI 1.60 to 2.20)) [5]. However, more severe side
effects were also experienced, requiring the withdrawal
of treatment (such as urticaria, nausea and vomiting)
and less serious but unpleasant side effects such as oral
and vaginal candidiasis, and gastrointestinal distur-
bances resulting from antibiotic treatment. These can
cause considerable discomfort and probably contribute
to women’s expressed preference to avoid antibiotics
use [15].
Once prophylaxis is discontinued, even after extended
periods, approximately 50–60 % of women will become
re-infected within 3 months [16, 17]. Thus, antibiotic
prophylaxis does not exert a long-term effect on the
baseline infection rate.
Rationale for use of Chinese herbal medicine
Chinese herbal medicine (CHM) has a recorded history
of treating the symptoms of UTIs for over 2000 years
[18]. More recent clinical research in China has provided
some supportive evidence that CHM can alleviate the
symptoms of UTIs [19–22] and reduce the rate of recur-
rence 1 year post-treatment from 30 % when antibiotics
were used alone to 4.4 % when antibiotics and CHM
were combined [20]. A recent Cochrane review of CHM
for RUTIs found some preliminary supportive data for
herbal interventions, but the trials were of poor quality
and further and more rigorous research was recom-
mended [23].
Rationale for the trial design
In accordance with MRC recommendations for the
investigation of poorly evidenced complex interventions
such as CHM [24], a strategic, phased, research-
development process is essential. The RUTI trial has
been conceived as a small scale feasibility trial to ex-
plore the treatment effects of CHM and to investigate
if CHM can be used and researched in primary care.
Research objectives
The key objectives for this study are as follows:
 To explore the feasibility of developing, implementing
and evaluating a CHM intervention within the
primary care networks with particular regard to
recruitment, referral patterns, patient compliance,
the use of a plausible herbal placebo and dropout
rates
 To evaluate the acceptability and sensitivity to
change of different outcomes measures and to
provide a provisional estimation of any effect size
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relating to CHM treatment that could inform a
more definitive future study
 To use nested qualitative research and quantitative
quality of life outcome measures to explore the
experience of women taking CHM and to
investigate any perceived differences between the
delivery of standardised remedies via GP practice
nurses and individualised remedies via CHM
practitioners
Methods/design
The trial has two separate but linked arms (see Additional
file 1). Forty women from the Wessex, South and
Northwest London and the Brighton and Hove areas
of the Clinical Research Network (CRN) will be randomised
to take traditional individualised herbal prescriptions
following consultation with a registered CHM practi-
tioner at a private clinic. Forty women from Wessex
will be randomised to standardised ‘prescriptions’ of
herbal capsules administered via nurses and doctors
from GP practices. Both arms will have equal allocation
to active and placebo medications. The trial is fully
blinded with only the herbal dispensaries knowing the
treatment allocation of the women.
Eligibility
A medical record search will be conducted for women
who have had more than two prescriptions for trimetho-
prin or nitrofurantoin within the last 12 months and/or
have been recorded as having recurrent UTIs.
A standard letter will be sent to these women with
the Patient Information Sheet explaining the trial
(Additional file 2). They will be contacted by the trial
manager who will explain the trial more fully and as-
sess eligibility. If the women are both eligible and in-
terested an appointment will be made at the primary
care site or at the appropriate clinic where written
consent will be taken (Additional file 3).
Inclusion/exclusion criteria
Women will be eligible for the trial if they meet all of
the following criteria:
 are over 18 years and under 65 years of age
 have reported three or more uncomplicated
recurrent lower UTIs in the previous 12 months
 have had at least one episode documented as being
suspected or confirmed as a bacterial UTI by a GP
Women will be ineligible if they have any of the following
criteria:
 have symptoms of complicated UTIs, such as acute
pyelonephritis.
 have known hepatic or renal disease
 are pregnant or breast feeding
 have diabetes
 are taking drugs which may interact with Chinese
herbal medicine: cardiac glycosides (digoxin),
warfarin and lithium
 have psychosis, dementia or terminal illness that
may prevent completion of the symptom diaries
 have commenced a new treatment (conventional or
complementary or alternative medicine (CAM)) for
RUTIs in the previous 6 months.
Randomisation and blinding
Computer-generated block randomisation to either
verum (active) or placebo CHM treatment will be per-
formed with random block sizes of two, four, or six par-
ticipants to ensure equal numbers in groups and to
prevent the study team and the dispensary team from
being able to predict a pattern to the randomisation.
In the standardised arm, this randomisation sequence
will be used by the manufacturer to code the herbal cap-
sules prior to the capsules being sent to GP practices.
Capsules will be dispensed according to this sequence,
and a record of the batch number recorded by the prac-
tice nurse.
For the individualised arm, the randomisation sequence
will be stored at the herbal dispensary in opaque sealed
envelopes and kept in a safe place only accessible to a
designated person. On receiving the formula by email, this
person will open the envelope and inform the herbal
dispensary whether the trial participant is to receive the
placebo or active herbs. A record of this allocation will be
kept by the designated person so that repeat prescriptions
will be allocated to the same arm.
Intervention
All women taking part will be able to consult with their
GPs and, if necessary, use conventional medicines such
as antibiotics for acute infections. Antibiotic use will be
recorded as one of the trial outcomes. These can be
taken in conjunction with the ‘acute’ herbal treatment.
Participants in the standardised arm will receive ‘acute’
and ‘preventative’ herbal capsules (Size 0, hypromellose
capsules) to be used during and between instances of
infection. Matching placebo capsules have been prepared
containing therapeutically inert sugar beet fibre. In total,
16 weeks of preventative herbal capsules will be allocated
to each participant, with an additional 4 weeks of ‘acute’
capsules to be used in the instance of a UTI occurring.
The individualised arm of the trial will follow routine
practice of CHM, which involves a practitioner writing
an individualised herbal prescription typically compris-
ing between ten and 15 herbs selected from the Chinese
herbal material medica. The selection of herbs is
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contingent upon a full CHM differential diagnosis made
after a detailed consultation process. The formula used
will also change over time to address the changing clin-
ical presentation of the patient.
After the consultation with the CHM practitioner
verum or placebo herbal medicines will be dispensed
as concentrated herbal granules to be taken twice a
day. Each dose will be separately packaged in a sealed
foil sachet. These granules dissolve in hot water for
patients to drink as an herbal decoction. The practi-
tioner may allocate preventative treatment with a
clearly labelled standby for an acute infection. Women
allocated to placebo treatment will receive identically
packaged granules derived from therapeutically inert
food colourings and flavourings. Once re-constituted,
these placebo herbs resemble the colour and the
strong taste and smell of the verum formulae.
Standardised trial medicines
Chinese herbal medicine in the UK involves the use of
plant-based herbal medicines. The standardised herbal for-
mulae have been developed through expert consultation
and a literature review conducted prior to the trial.
Each formula consists of three herbs (see Additional
file 4).
These two formulae are comprised of the following
herbs:
RUTI‐a :
Bai Hua She She Cao Herba Hedyotis Diffusað Þ
40% of the Formulationð Þ
Huang Bai Cortex Phellodendron Amurenseð Þ
20% of the Formulationð Þ
Jin Qian Cao Hebra Lysimachia Christinaeð Þ
40% of the Formulationð Þ
RUTI‐p :
Huang Qi Radix Astragalus Membranaceusð Þ
50% of the Formulationð Þ
Wu Yao Radix Lindera Strychnifoliað Þ
25% of the Formulationð Þ
Ku Shen Radix Sophorae Flavescentisð Þ
25% of the Formulationð Þ
In terms of modern pharmacology, the herbal formulae
are reported to have the following main functions (see
Additional file 4):
RUTI-a has antibacterial and anti-inflammatory
actions.
RUTI-p has immune enhancing, anti-inflammatory,
antibacterial, and mildly diuretic actions.
These standardised herbs will be administered as 0.4 g
capsules (two pills taken twice a day (b.d.) for preventative
treatment, and four pills taken four times a day (q.d.) in
the event of an acute infection).
Concealment and emergency unblinding
Concealment will be maintained with packaging in the
standardised arm that does not provide any information
as to the contents and in the individual arm by the use
of identical packaging and by the participant’s herbs not
being seen by the CHM practitioner.
Each woman enrolled will be provided with an emer-
gency unblinding card with information on how to access
the trial team if required.
Emergency unblinding will be possible by a member of
the study team not conducting study assessments, who
will use the participant ID number and check allocation
by accessing the centralised allocation list stored at the
herbal dispensary. Unblinding will be required in case of
the following:
 A compelling medical need as assessed by the
treating medical doctor, e.g. a serious adverse event
(SAE) has occurred, and the treatment allocation is
required to inform subsequent clinical care
 Ingestion of study products by a child
 Ingestion of excessive amounts of study products
either by the participant or by an adult not
participating in this study.
Outcomes (see Figs. 1 & 2)
Primary outcome measures
The primary outcomes will be the number episodes
of recurrent UTIs during the trial period and in the
6 months of follow up and the number of days of
symptoms rated moderately bad or worse according
to the patient diaries [10]. These will be assessed by
symptom diaries, which will indicate the severity of
acute and recurrent UTI symptoms (reporting dysuria,
haematuria, frequency during day and night, ‘smelly
urine’, ‘tummy pain’, generally feeling unwell, and re-
striction of daily activities). These diaries have been
used in this format for acute respiratory and urinary
tract infections and have been validated and shown to
be sensitive to change [2, 10].
In addition, participants will also be asked to complete
an end-of-month diary in which they record the number
of days with symptoms, changes in presentation, time
lost from work, and how easy it has been to comply with
the herbal medicine regime. These diaries will provide
information on the rate and severity of acute infection
but also on the impact of low-grade, chronic infection
on the lives of women. Participants will be asked to
complete both an acute and a monthly diary for the
6-month follow-up to the trial to enable the evalu-
ation of any longer-term changes in infection rates.
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Secondary outcomes include the following:
 The use of antibiotics for acute UTIs elicited from
symptom diaries and cross-referenced with GP
notes
 The Credibility/Expectancy questionnaire, which
is used to assess participant attitudes on the
effectiveness of CHM prior to and on completion
of the trial [25]
 The Morisky Medication Adherence Scale, which
is used to assess compliance with the herbal
medicines. In addition participants will be asked to
return all herbal containers including those that
are empty and those with any unused herbal
capsules or granules. These will be counted to
help assess whether herbal medicines were taken
as instructed.
 At the end of trial, a Global Ratings of Change
pro forma will be used to assess participant
perceptions of the overall change in the frequency
and severity of their urinary symptoms. An 11-
point Likert scale will be used to assess these
changes and an improvement of two or more
points will be considered as a clinically important
change [26].
 Liver (ALT) and renal (serum creatinine) function
tests will be conducted at weeks 0, 4 and 16. Blood
results will be used to assess safety of the herbal
Fig. 1 RUTI flow diagram
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preparations to ensure that no change in kidney or
liver functions occurs (each site was given the specific
normal reference ranges for their associated NHS
laboratory where the blood was processed.)
 Economic and quality of life assessment using the
validated EQ5D outcome measure.
 An assessment of blinding using the Bang blinding
index (CHM practitioner only).
 Two nested qualitative studies will also be
conducted during this trial. On completion of the
trial, semi-structured phenomenological interviews
will be conducted with purposively sampled women
from all four groups to provide an in-depth exploration
of their subjective experiences of taking CHM and
conventional care during the trial. We will also
investigate the enablers and barriers that affected
women’s decisions to participate in the trial. A
second study will include interviews of GP practice
nurses to explore their experiences of delivering
CHM in a clinical trial conducted in primary care.
Research ethics and governance
Obtaining regulatory approval from the Research
Ethics Committee, the MHRA, and NHS Research and
Development has been an important outcome for this
trial. Initial submissions were made to the MHRA in
October 2014, and final approval was granted in
November 2015. Requests for ethical approval were
made in August 2014 and multi-centre approval was
granted by the London Surrey Borders Research Ethics
Committee in December 2015. (Ref: 14/LO/1425 and
by the MHRA (EudraCT number: 2013-004657-24).
The lead research and development organisation was
the Wessex Clinical Research Network. A more de-
tailed account of the unique challenges required to
gain these approvals has been provided in the discus-
sion section. In addition the following ethical issues
required clarification:
All women participating in the trial will be able to con-
tinue their pattern of usual care alongside taking CHM
(see Additional files 2 and 3). Antibiotics can be accessed
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from their GPs as a rescue package in the event of a
serious UTI occurring.
All herbs to be used in the individualised arm of the
trial are currently in daily usage within the UK under
Regulation 3 of The Human Medicines Regulations 2012
(formally Section 12(1) of the Medicines Act 1968),
which permits unlicensed herbal remedies to be made
up and supplied by a practitioner to meet the needs of
an individual patient following a one-to-one consult-
ation. Regulation 3 remedies are not subject to a regime
of specific safety or quality requirements and currently




All point-of-care test specimens, evaluation forms,
reports and other records will be identified in a manner
to maintain participant confidentiality and in accordance
with the Data Protection Act 1998. All records will be
kept in a secure storage area on site with access restricted
only to staff delegated duties on the study. Clinical infor-
mation will not be released without the written permission
of the participant, except in cases of emergency or as ne-
cessary for monitoring and auditing by the study sponsor.
All study staff must comply with the Data Protection Act
1998 and abide by the requirements of the University of
Southampton relating to the collection, storage, process-
ing and disclosure of personal information. Any data from
this research will be stored according to the University of
Southampton Data Protection policy. Written and digitally
recorded data will be stored on a password protected
computer that will be kept in a secure environment. Any
papers connected with this trial will be kept in secure
University storage for 10 years and will only be viewed by
the research team.
Data monitoring committee
An independent data monitoring committee has been
established to review the results of any abnormal blood
tests, adverse events, and other relevant data to decide
whether or not the trial should continue. The committee
will comprise of a medical statistician, a consultant
urologist and a medical Toxicologist.
Data analysis
The primary outcomes from this study are descriptive,
relating to the feasibility of recruitment, the acceptability
of randomisation, study medications and outcome mea-
sures including patient diaries, and the retention of
randomised patients in the study. We will also describe
additional data on adverse effects, antibiotic use and
adherence to medication, beliefs and expectations of par-
ticipants, health economics and changes in quality of life.
Although the trial is not powered to provide estimates
of effect, exploratory analysis will be undertaken to esti-
mate any effect of individualised, standardised and pla-
cebo treatments on the primary outcomes of reducing
the frequency and severity of recurrent UTIs.
Continuous outcomes will be explored using linear
regression, provided the assumptions underlying the model
are met. If not, non-parametric methods will be used.
Binary measures will be analysed using logistic regression
and count models using an appropriate count distribution.
All analyses will be on an intention-to-treat basis and will
control for important confounders. Results will be reported
in accordance with CONSORT guidelines.
We will analyse any missing data to see if any recur-
rent patterns emerge, and we will record the numbers
and reasons given for participant withdrawal or loss to
follow-up, as these are key feasibility outcomes that will
inform a larger trial.
Data from the trial will be entered into SPSS 22 for
Windows (SPSS Inc., Chicago) and the analysis com-
pleted using Stata 14 (StataCorp).
Nested qualitative study
All qualitative interviews will be digitally audio-recorded
(with permission) and transcribed verbatim with the
participant details being anonymised.
The qualitative research investigating the experience
of trial participants will not commence until all the
quantitative outcomes have been completed. Those con-
ducting the interviews will remain blinded to any quanti-
tative analysis of the participants’ case record forms. An
interpretative phenomenological analysis (IPA) [27] will
be used to explore the subjective experiences of these
women with a particular emphasis on their perceptions
of any changes in health and wellbeing during the trial,
the meanings attributed to these changes, and the ratio-
nales they used to explain them-including their attitudes
and beliefs in relation to CHM.
In addition, in order to explore the feasibility of
administering CHM in primary care, practice nurses
involved in the trial will also be interviewed. An induct-
ive thematic analysis will be undertaken to identify key
themes that reflect the shared experiences of nurses in-
volved in the trial [28, 29].
Discussion
The regulatory status of herbal medicinal products being
used within a research context in the UK was far from
clear at the outset of this study. After discussion with
the Medicines and Healthcare products Regulatory
Agency (MHRA), the body responsible for regulating
clinical trials in the UK, it became clear that any pre-
formulated herbal product designed for use in a clinical
trial setting was considered as an Investigational Medicinal
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Product (IMP) and had to abide by the regulatory re-
quirements of a clinical trial of an IMP (CTIMP). These
requirements have been established for testing novel
pharmaceuticals and present a significant challenge to
herbal medicinal products for a number of reasons.
First, whereas a pharmaceutical usually involves a single,
refined, active compound, herbal medicines may contain
hundreds or even thousands of compounds of variable
consistency that may contribute to any therapeutic effect
observed. Second, the production of a herbal medicine in-
volves a complex trail from ‘fields to pharmacy’ that cannot
replicate the sterile, controlled facilities of a pharmaceutical
company that is bound by stringent, properly audited, and
certified Good Manufacturing Practices (GMP). Third, the
stability of an herbal product over time is difficult to assess,
despite generous shelf lives being ascribed to them by
herbal manufacturers.
These challenges were gradually overcome through
on-going dialogue with the MHRA. Eventually it was
agreed that key marker compounds could be used to
authenticate an herb used in a trial, and that these com-
pounds should also be used to establish the stability of
the finished herbal product. Second, it is possible to
locate herbal manufacturers in China and Taiwan who
have either EU or Australian certification for GMP. This
included Good Agricultural Practice (GAP), as well as
guaranteeing quality assured processes of production for
the herbal granules to be used in the trial. These ensured
that the herbs were properly evaluated with regard to
authentication, bio-burden, and contamination with heavy
metals or pharmaceuticals, and that the finished product
met pre-agreed standards.
However, as this feasibility study was considered a
CTIMP, any products being tested were required to be
manufactured by a company with MHRA Manufacturers
Authorisation for CTIMPs, which would be able to pro-
vide the extensive and detailed information required for
the Investigators Brochure that provides a key part of
the application for a trial license. Fortunately, we were
able to collaborate with Essential Nutrition Ltd., a com-
pany with a CTIMP Manufacturers Authorisation and
experience of producing herbal and nutritional supple-
ments and a Qualified Person who could take legal
responsibility for signing out the finished product to be
used in the clinical trial. We will discuss the intricacies,
complexities, and fairly substantial costs involved in sat-
isfying these regulatory processes in more details in a
separate paper.
Whilst pre-formulated herbal products were considered
as CTIMPs, individualised herbal prescriptions were in-
stead considered as being routine practice of herbal medi-
cine and were not compelled to go through the same
stringent regulatory processes. This is an important prece-
dent for future research on herbal medicines.
As the trial aims to recruit via NHS pathways, regulatory
approval was also needed from an NHS Research Ethics
Committee (REC) and an NHS Research and Development
(R & D) committee. In addition, ethical approval from a
Southampton University Ethics Committee was also
required.
The RUTI trial is the first trial in the UK of a Chinese
herbal remedy registered as an Investigational Medicinal
Product. Obtaining ethical and regulatory approval has
been a challenging educational and research experience
for us as researchers and the various regulatory author-
ities with who we have worked closely in co-operation.
Our first major outcome is that we have managed to
negotiate the complex process successfully. This means
that we have established a precedent to enable subse-
quent trials of CHM to take place. The RUTI trial is
now recruiting, and we will be able to provide data on
the feasibility and safety of using and researching CHM
within primary care. This trial will also provide a com-
parison of individualised versus standardised herbal
treatment that will help inform the design of future trials
in herbal medicine. Finally, the RUTI trial will provide
provisional estimates of the variance of change in con-
tinuous outcomes which, if warranted, could be used to
inform a power calculation for a larger, more definitive
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